Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Lyons

Showing results (191-200 of 206) with videos related to

Pageof 21
Sort By:
Cell Systems|February 12, 2026
Translation elongation as a rate-limiting step of protein productionElijah F Lyons, Lou C Devanneaux, Ryan Y Muller, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2016
Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumourAndrew J Wagner, Mark Agulnik, Michael C Heinrich, et al.
Blood|June 16, 2010
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cellsRuriko Tanaka, Matthew S Squires, Shinya Kimura, et al.
British Journal of Haematology|May 29, 2010
AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disordersMark A Dawson, Jayne E Curry, Kelly Barber, et al.
Molecular Cancer Therapeutics|October 29, 2014
Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma modelsTomoko Smyth, Kim H T Paraiso, Keisha Hearn, et al.
Plos One|October 11, 2011
Induction of eosinophil apoptosis by the cyclin-dependent kinase inhibitor AT7519 promotes the resolution of eosinophil-dominant allergic inflammationAna L Alessandri, Rodger Duffin, Andrew E Leitch, et al.
Molecular Cancer Therapeutics|April 27, 2018
ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor GrowthGeorge A Ward, Edward J Lewis, Jong Sook Ahn, et al.
Molecular Cancer Therapeutics|April 29, 2010
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growthKyla M Grimshaw, Lisa-Jane K Hunter, Timothy A Yap, et al.
Leukemia & Lymphoma|October 19, 2016
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials GroupMatthew D Seftel, John Kuruvilla, Tom Kouroukis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2014
A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK studyLucas Moreno, Lynley V Marshall, Andrew D J Pearson, et al.
Pageof 21

Showing results (191-200 of 206) with videos related to

Sort By:
Pageof 21
Cell Systems|February 12, 2026
Translation elongation as a rate-limiting step of protein productionElijah F Lyons, Lou C Devanneaux, Ryan Y Muller, et al.
European Journal of Cancer (Oxford, England : 1990)|May 9, 2016
Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumourAndrew J Wagner, Mark Agulnik, Michael C Heinrich, et al.
Blood|June 16, 2010
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cellsRuriko Tanaka, Matthew S Squires, Shinya Kimura, et al.
British Journal of Haematology|May 29, 2010
AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disordersMark A Dawson, Jayne E Curry, Kelly Barber, et al.
Molecular Cancer Therapeutics|October 29, 2014
Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma modelsTomoko Smyth, Kim H T Paraiso, Keisha Hearn, et al.
Plos One|October 11, 2011
Induction of eosinophil apoptosis by the cyclin-dependent kinase inhibitor AT7519 promotes the resolution of eosinophil-dominant allergic inflammationAna L Alessandri, Rodger Duffin, Andrew E Leitch, et al.
Molecular Cancer Therapeutics|April 27, 2018
ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor GrowthGeorge A Ward, Edward J Lewis, Jong Sook Ahn, et al.
Molecular Cancer Therapeutics|April 29, 2010
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growthKyla M Grimshaw, Lisa-Jane K Hunter, Timothy A Yap, et al.
Leukemia & Lymphoma|October 19, 2016
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials GroupMatthew D Seftel, John Kuruvilla, Tom Kouroukis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2014
A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK studyLucas Moreno, Lynley V Marshall, Andrew D J Pearson, et al.
Pageof 21